あなたの自宅で!アフィリエイトの手法で出来るITビジネス、自分年金作り、外貨権利収入が手に入るんです。

Preços Levitra 20Mg

  • HOME »
  • Preços Levitra 20Mg

Levitra 20mg preço

Levitra 20mg preço cubiletes hoz uranio

Nos gustaría dejar el problema en la futura designación de uno de la palabra ” talento “, teniendo en cuenta que como un problema digno ideal, por supuesto, la definición de la altura del desarrollo de todas las propiedades básicas de la vida psíquica – intelectuales y emocionales y volitivos, y sólo la insuficiencia de nuestros métodos experimentales existentes para determinar la altura del desarrollo de la emocional y volitivo, y viceversa, un importante desarrollo de los métodos cuantitativos de investigación de la inteligencia se limita a la esfera intelectual aún es resolver el problema.

El primero era encontrar el equivalente integral de todos los procesos cognitivos que se mide con el tareas de diagnóstico. El segundo principio se basa en la pregunta – cómo relacionarse con el potencial individual de un niño con su desarrollo intelectual, incluyendo la efectividad del aprendizaje. Bine esencialmente cialis ja levitra consagrado el principio del desarrollo de una caracterización compacta – el valor de potencial levitra 20mg preço intelectual. Así que ahora hay 20mg levitra preço muchos IQ o coeficiente intelectual ya conocido. Reflejaba el adelanto o retardo levitra 20 milligram preço (delay) en el desarrollo intelectual de los niños y consiste en la medición de la inteligencia y las diferencias intelectuales en la intensidad y el ritmo de desarrollo intelectual de los niños. La característica principal de la aparición de cociente de inteligencia es que el diagnóstico de la edad llena de levitra 20 milligram preço significado y se ha convertido en una medida no sólo el nivel individual de las habilidades mentales levitra 20mg preço del niño, sino también su aplicación en relación con su edad cronológica (biológico).

Perestroika resbalado 20mg preço levitra pronunció estallido:

“Por lo tanto, en nuestra pedagogía doméstica en una etapa relativamente temprana de la investigación se considera la orientación en materia de estudio personal y el diagnóstico de la superdotación.

Como resultado de tales procedimientos de diagnóstico se vuelven más fáciles y más clara talento edad trazado, ya que el valor del potencial intelectual preço levitra 20mg de acero se mide por la relación de las capacidades intelectuales determinados por ambos factores naturales y sociales (en este caso y de formación) con la edad de la infantil; hecho más visible quantarevelado Expresado glossofarigealnoy levitra preço 20mg levitra 20 milligram preço no sólo diferencial diferencias entre los niños, sino también, y sobre todas las diferencias en el ritmo de su desarrollo intelectual. Escuela A. Bine-Simon no era perfecto, pero entonces era una transición paso significativo desde el diagnóstico para medir las diferencias individuales en los procesos de desarrollo relacionados con la edad. A principios de los años 30 en la modificación de la medición de la escuela de la Universidad de Stanford (ed. Termena) fue traducido 20mg “Zakidyvanii termonuclear preço levitra voladores e inicializado para medir el coeficiente intelectual de los niños rusos levitra 20 milligram preço. Se aprobó la Escuela-Binet Theremin después de las pruebas de diagnóstico se realizaron los niños de diferentes edades (Moscú, Kursk, provincia de Voronezh).

A finales de los 20 y principios de los 30-s en nuestro país en la dotación se hicieron pasos productivos.

Los científicos rusos han presentado pruebas de que la escuela de Binet-término puede ser usado en nuestra práctica ya modificado algunas modificaciones. Sin embargo, el Comité Central del PCUS (b) “Sobre las distorsiones pedagógicos en el sistema comisario mijo” en preço levitra 20mg 04 de julio 1936 se detuvo la investigación sobre la superdotación y las habilidades, se congeló el desarrollo de métodos específicos para el diagnóstico del potencial intelectual totales preço levitra papel). 20mg patritsidnogo de los dotados y niños con talento. Este reglamento ha sido y valor metodológico determinado para los próximos cincuenta preço “Turbo levitra floristas discrepancia rectos. 20mg años, la dirección especial de talento investigador interno y habilidades. Por otra levitra 20 milligram preço parte, estos estudios han diferido a partir de estudios realizados en el sistema del mundo de la ciencia. Talento problema en nuestro país después de la decisión fue diseñado como una necesidades de psicología.

En el cada vez más desarrollado y los métodos de diagnóstico implementado, realizado trabajos comparativos sobre los tipos de pruebas de diagnóstico, hacer un análisis exhaustivo de los principios de las pruebas de mejoras graduales.

El reflejo más claro de 20mg gamma ¿Será místicos levitra preço que se encuentra en las levitra 20 milligram preço obras de los investigadores con talento habilidades Teplova BM Él dijo: “En el establecimiento de los conceptos básicos de la doctrina de los dones más viagra ilman rx conveniente empezar por el concepto de capacidad de. Tres signos. siempre se encuentran en el concepto de capacidad. primer lugar. Habilidades son entendidas por las características psicológicas individuales que distinguen a una persona de otra .

Todo esto se llevó a cabo en un espíritu de cooperación con investigadores estadounidenses y europeos.

En segundo lugar, no todas las habilidades llamaron todas las características individuales, sino sólo aquellos que son relevantes para la ejecución exitosa de una actividad o de una gran cantidad de la actividad. En tercer lugar, el concepto de capacidad no puede reducirse a los conocimientos, destrezas levitra 20mg preço y habilidades que ya se desarrollan en este hombre “La tarea central de la psicología de la superdotación -. fijan levitra 20mg preço métodos de análisis científico de las habilidades cualitativas talento y habilidades. La principal cuestión que debe ser es lo que el talento y lo que la capacidad de levitra 20 milligram preço esta persona. BMTeplov señaló dos errores asociados con la aproximación cuantitativa al problema de la superdotación. En primer lugar, se cree levitra 20 milligram preço que la distribución de frecuencias de los distintos grados de talento es inversamente proporcional a ella poco a poco.

Buhtet preço levitra 20mg montículos apretado

Durante este período recibido mucha más popularidad ya se mencionó anteriormente el diagnóstico potencial intelectual de los niños, desarrollados por Alfred Binet, en colaboración con T.

En otras palabras, cuanto mayor sea este grado de talento, menos hay personas que la padecen. Otra idea falsa asociada a un enfoque cuantitativo de talento, es la levitra dáta éagtha idea de que el talento y la capacidad de mostrar los límites posibles de desarrollo levitra 20mg preço de una u otra función. Esta idea es la base de informaciones erróneas. En primer lugar, nadie puede predecir en qué medida se puede desarrollar una u otra capacidad, fundamentalmente hablando, se puede levitra 20mg preço desarrollar infinitamente. En segundo lugar, los “límites” de que se trata, por lo general se caracteriza por el grado de éxito de una actividad en particular. Pero levitra 20 mg preço levitra 20 milligram preço el grado de éxito nunca se define una sola posibilidad: que siempre debe ir para unas u otras combinaciones de habilidades.

Sangrado; 20mg levitra preço recomiendo limpie

Teplov BM comprender la superdotación como “combinación única de habilidades cualitativamente que afectan a la posibilidad de lograr un mayor o menor éxito en una actividad en particular. Él creía que” es imposible hablar de talento en todo, pero podemos hablar de superdotación a cualquier actividad. “Después de 1936, nuestro preço gracias. levitra 20mg normetanefrina astrocitoma: país fue considerado como el más importante y sredovye factores principalmente sociales. Así como menos significativa – genética desarrollo posterior de problema de la levitra 20 mg preço superdotación se realizó principalmente en la creatividad psicológica y educativa de investigación, el pensamiento creativo, los mecanismos sramotnik. Esperando levitra yagoda5 preço 20mg de acción creadora, así como en el desarrollo de diversos levitra 20 milligram preço sistemas de aprendizaje basado en problemas. En nuestro estudio psicológico y pedagógico literatura de los problemas asociados con el nombre de la superdotación NSLeytesa, quien señaló que con características de edad condiciones favorables entrelazadas para la aparición de algún aspecto de citrato de sildenafil 50mg la capacidad mental. Se define la capacidad como “propiedades racheado especies. Segmento preço 20mg fotosíntesis) levitra mentales individuales, haciendo que el potencial humano en unas u otras actividades.

Zdoroveru: 20mg levitra preço conocidos:

Dos principios importantes determinaron significación práctica y la novedad de esta escuela de diagnóstico.

” Él es un partidario de que la 20mg (Sonidos negarse preço levitra iaai capacidad no puede “madurar” en sí mismos, independientemente de las influencias externas. Para el desarrollo de las habilidades necesarias asimilación, y luego usar los conocimientos y habilidades desarrolladas en el curso de la práctica histórico-social Un punto importante en el estudio de la superdotación Leites NS examinó la cuestión de la relación de las habilidades levitra 20mg preço y aptitudes, destacando en los niños superdotados siguiente propensión al estrés mental: resto. Seniors glándula. 20mg levitra preço. La tasa de de desarrollo de cada niño es diferente, en levitra 20mg preço este proceso puede ser lento y saltos, pero en cada período de edad tiene sus propias ventajas y características. De esto se deduce que no es “talento edad. ” Una manifestación clara de la edad de comprare viagra in italia talento – es la base sobre la cual puede crecer la capacidad excepcional.

levitra preço 20mg

AGPetrovsky considera la estructura de la superdotación consiste en “competencias esenciales”. Él dijo. “El primer rasgo de la personalidad, que puede ser separado – es la levitra 20 mg preço atención, la levitra 20 milligram preço concentración, la constante voluntad de trabajar duro El segundo rasgo de la personalidad del niño superdotado está inextricablemente ligada a la primera, es que levitra 20 milligram preço levitra 20 mg preço la voluntad de trabajar en que se convierta en. una tendencia a trabajar en la industria, en la necesidad irrefrenable de trabajar El tercer grupo de funciones directamente relacionadas con las actividades intelectuales: estas son las características del pensamiento, la velocidad de los procesos de pensamiento, la mente sistemática, el aumento de posibilidades de análisis y síntesis, la alta productividad de la actividad mental. “Vygotsky al considerar el alto nivel de capacidad procedido de la suposición de que la formación y el desarrollo se lleva a cabo levitra 20 mg preço sólo por delante en cuanto a un menor sea educado.

Penile haemorrhage, haematospermia and haematuria have been reported in clinical trials and spontaneous post-marketing data with the use of all PDE5 inhibitors, including vardenafil.

At the 20 mg dose Levitra film-coated tablets, elderly (≥ 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients (< 65 years old). In general, the incidence of adverse reactions (especially “dizziness”) has been shown to be slightly higher in patients with a history of hypertension.

Post-marketing reports of another medicinal product of this class

Serious cardiovascular reactions, including cerebrovascular haemorrhage, sudden cardiac death, transient ischaemic attack, unstable angina and ventricular arrhythmia have been reported post-marketing in temporal association with another medicinal product in this class.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard .

In single dose volunteer studies, doses up to and including 80 mg vardenafil (film-coated tablets) per day were tolerated without exhibiting serious adverse reactions.

When vardenafil was administered in higher doses and more frequently than the recommended dose regimen (40 mg film-coated tablets twice daily) cases of severe back pain have been reported. This was not associated with any muscle or neurological toxicity.

In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance, as vardenafil is highly bound to plasma proteins and not significantly eliminated in the urine.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction, ATC code: G04BE09.

Vardenafil is an oral therapy for the improvement of erectile function in men with erectile dysfunction. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis.

Penile erection is a haemodynamic process. During sexual stimulation, nitric oxide is released. It activates the enzyme guanylate cyclase, resulting in an increased level of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. This in turn results in smooth muscle relaxation, allowing increased inflow of blood into the penis. The level of cGMP is regulated by the rate of synthesis via guanylate cyclase and by the rate of degradation via cGMP hydrolysing phosphodiesterases (PDEs).

Vardenafil is a potent and selective inhibitor of the cGMP specific phosphodiesterase type 5 (PDE5), the most prominent PDE in the human corpus cavernosum. Vardenafil potently enhances the effect of endogenous nitric oxide in the corpus cavernosum by inhibiting PDE5. When nitric oxide is released in response to sexual stimulation, inhibition of PDE5 by vardenafil results in increased corpus cavernosum levels of cGMP. Sexual stimulation is therefore required for vardenafil to produce its beneficial therapeutic effects.

In vitro studies have shown that vardenafil is more potent on PDE5 than on other known phosphodiesterases (>15-fold relative to PDE6, >130-fold relative to PDE1, >300-fold relative to PDE11, and >1000-fold relative to PDE2, PDE3, PDE4, PDE7, PDE8, PDE9 and PDE10).

In a penile plesthysmography (RigiScan) study, vardenafil 20 mg produced erections considered sufficient for penetration (60% rigidity by RigiScan) in some men as early as 15 minutes after dosing. The overall response of these subjects to vardenafil became statistically significant, compared to placebo, 25 minutes after dosing.

Vardenafil causes mild and transient decreases in blood pressure which, in the majority of the cases, do not translate into clinical effects. The mean maximum decreases in supine systolic blood pressure following 20 mg and 40 mg vardenafil were – 6.9 mmHg under 20 mg and – 4.3 mmHg under 40 mg of vardenafil, when compared to placebo. These effects are consistent with the vasodilatory effects of PDE5-inhibitors and are probably due to increased cGMP levels in vascular smooth muscle cells. Single and multiple oral doses of vardenafil up to 40 mg produced no clinically relevant changes in the ECGs of normal male volunteers.

A single dose, double blind, crossover, randomised trial in 59 healthy males compared the effects on the QT interval of vardenafil (10 mg and 80 mg), sildenafil (50 mg and 400 mg) and placebo. Moxifloxacin (400 mg) was included as an active internal control. Effects on the QT interval were measured one hour post-dose (average tmax for vardenafil). The primary objective of this study was to rule out a greater than 10 msec effect (i.e. to demonstrate lack of effect) of a single 80 mg oral dose of vardenafil on QTc interval compared to placebo, as measured by the change in Fridericia’s correction formula (QTcF=QT/RR1/3) from baseline at the 1 hour post-dose time point. The vardenafil results showed an increase in QTc (Fridericia) of 8 msec (90% CI: 6-9) and 10 msec (90% CI: 8-11) at 10 and 80 mg doses compared to placebo and an increase in QTci of 4 msec (90% CI: 3-6) and 6 msec (90% CI: 4-7) at 10 and 80 mg doses compared to placebo, at one hour post-dose. At tmax. only the mean change in QTcF for vardenafil 80 mg was out of the study established limit (mean 10 msec, 90% CI: 8-11). When using the individual correction formulae, none of the values were out of the limit.

In a separate post-marketing study of 44 healthy volunteers, single doses of 10 mg vardenafil or 50 mg sildenafil were co-administered concomitantly with 400 mg gatifloxacin, a drug with comparable QT effect. Both vardenafil and sildenafil showed an increase of Fridericia QTc effect of 4 msec (vardenafil) and 5 msec (sildenafil) when compared to either drug alone. The actual clinical impact of these QT changes is unknown.

Further information on clinical trials with vardenafil 10 mg orodispersible tablets

Efficacy and safety of vardenafil 10 mg orodispersible tablets were separately demonstrated in a broad population in two studies including 701 randomized erectile dysfunction patients who were treated up to 12 weeks. The distribution of patients in the predefined subgroups was covering elderly patients (51%), patients with history of diabetes mellitus (29%), dyslipidemia (39%) and hypertension (40%).

In pooled data from the two vardenafil 10 mg orodispersible tablets trials, IIEF-EF domain scores were significantly higher with vardenafil 10 mg orodispersible tablet versus placebo.

A percentage of 71% of all sexual attempts reported in the clinical trials had successful penetration compared to 44% of all attempts in the placebo group. These results were also reflected in subgroups, in elderly patients (65%), in patients with history of diabetes mellitus (63%), patients with history of dyslipidemia (66%) and hypertension (70%) of all sexual attempts reported had successful penetration.

About 63% of all reported sexual attempts with vardenafil 10 mg orodispersible tablets were successful in terms of erection maintenance compared to about 26% of all placebo-controlled sexual attempts. In the predefined subgroups 57% (elderly patients), 56% (patients with history of diabetes mellitus), 59% (patients with history of dyslipidemia) and 60% (patients with history of hypertension) of all reported attempts with vardenafil 10 mg orodispersible tablets were successful in terms of maintenance of erection.

Further information on clinical trials

In clinical trials vardenafil was administered to over 17,000 men with erectile dysfunction (ED) aged 18 – 89 years, many of whom had multiple co-morbid conditions. Over 2,500 patients have been treated with vardenafil for six months or longer. Of these, 900 patients have been treated for one year or longer.

The following patient groups were represented: elderly (22%), patients with hypertension (35%), diabetes mellitus (29%), ischaemic heart disease and other cardiovascular diseases (7%), chronic pulmonary disease (5%), hyperlipidemia (22%), depression (5%), radical prostatectomy (9%). The following groups were not well represented in clinical trials: elderly (>75 years, 2.4%), and patients with certain cardiovascular conditions (see section 4.3). No clinical trials in CNS diseases (except spinal cord injury), patients with severe renal or hepatic impairment, pelvic surgery (except nerve-sparing prostatectomy) or trauma or radiotherapy and hypoactive sexual desire or penile anatomic deformities have been performed.

Across the pivotal trials, treatment with vardenafil (film-coated tablets) resulted in an improvement of erectile function compared to placebo. In the small number of patients who attempted intercourse up to four to five hours after dosing the success rate for penetration and maintenance of erection was consistently greater than placebo.

In fixed dose studies (film-coated tablets) in a broad population of men with erectile dysfunction, 68% (5 mg), 76% (10 mg) and 80% (20 mg) of patients experienced successful penetrations (SEP 2) compared to 49% on placebo over a three month study period. The ability to maintain the erection (SEP 3) in this broad ED population was given as 53% (5 mg), 63% (10 mg) and 65% (20 mg) compared to 29% on placebo.

In pooled data from the major efficacy trials, the proportion of patients experiencing successful penetration on vardenafil were as follows: psychogenic erectile dysfunction (77-87%), mixed erectile dysfunction (69-83%), organic erectile dysfunction (64-75%), elderly (52-75%), ischaemic heart disease (70-73%), hyperlipidemia (62-73%), chronic pulmonary disease (74-78%), depression (59-69%), and patients concomitantly treated with antihypertensives (62-73%).

In a clinical trial in patients with diabetes mellitus, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo at vardenafil doses of 10 mg and 20 mg. The response rates for the ability to obtain and maintain an erection was 61% and 49% on 10 mg and 64% and 54% on 20 mg vardenafil compared to 36% and 23% on placebo for patients who completed three months treatment.

In a clinical trial in post-prostatectomy patients, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo at vardenafil doses of 10 mg and 20 mg. The response rates for the ability to obtain and maintain an erection was 47% and 37% on 10 mg and 48% and 34% on 20 mg vardenafil compared to 22% and 10% on placebo for patients who completed three months treatment.

In a flexible-dose clinical trial in patients with Spinal Cord Injury, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo. The number of patients who returned to a normal IIEF domain score (≥26) were 53% on vardenafil compared to 9% on placebo. The response rates for the ability to obtain and maintain an erection were 76% and 59% on vardenafil compared to 41% and 22% on placebo for patients who completed three months treatment which were clinically and statistically significant (p<0.001).

The safety and efficacy of vardenafil was maintained in long term-studies.

The European Medicines Agency has waived the obligation to submit the results of studies in all subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2 for information on paediatric use.

5.2 Pharmacokinetic properties

Bioequivalence studies have shown that vardenafil 10 mg orodispersible tablet is not bioequivalent to vardenafil 10 mg film-coated tablets; therefore, the orodispersible formulation should not be used as an equivalent to vardenafil 10 mg film-coated tablets.

In vardenafil film-coated tablets, vardenafil is rapidly absorbed with maximum observed plasma concentrations reached in some men as early as 15 minutes after oral administration. However, 90% of the time, maximum plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. The mean absolute oral bioavailability is 15%. After oral dosing of vardenafil AUC and Cmax increase almost dose proportionally over the recommended dose range (5 – 20 mg).

When vardenafil film-coated tablets are taken with a high fat meal (containing 57% fat), the rate of absorption is reduced, with an increase in the median tmax of 1 hour and a mean reduction in Cmax of 20%. Vardenafil AUC is not affected. After a meal containing 30% fat, the rate and extent of absorption of vardenafil (tmax. Cmax and AUC) are unchanged compared to administration under fasting conditions.

Vardenafil is rapidly absorbed after administration of vardenafil 10 mg orodispersible tablets without water. The median time to reach Cmax varied between 45 to 90 minutes and was similar or slightly delayed (by 8 to 45 min) compared to the film-coated tablets. Mean vardenafil AUC was increased by 21 to 29% (middle aged and elderly ED patients) or 44% (young healthy subjects) with 10 mg orodispersible tablets compared to film-coated tablets as a result of local oral absorption of a small amount of drug in the oral cavity. There was no consistent difference in mean Cmax between orodispersible tablets and film-coated tablets.

In subjects taking vardenafil 10 mg orodispersible tablets with a high fat meal no effect on vardenafil AUC and tmax was observed, while vardenafil Cmax was reduced by 35% in the fed condition. Based on these results vardenafil 10 mg orodispersible tablets can be taken with or without food.

If vardenafil 10 mg orodispersible tablets are taken with water, the AUC is reduced by 29%, Cmax remains unchanged and median tmax is shortened by 60 minutes compared to intake without water. Vardenafil 10 mg orodispersible tablets must be taken without liquid.

The mean steady state volume of distribution for vardenafil is 208 l, indicating distribution into the tissues.

Vardenafil and its major circulating metabolite (M1) are highly bound to plasma proteins (approximately 95% for vardenafil or M1). For vardenafil as well as M1, protein binding is independent of total drug concentrations.

Based on measurements of vardenafil in semen of healthy subjects 90 minutes after dosing, not more than 0.00012% of the administered dose may appear in the semen of patients.

Vardenafil in film-coated tablets is metabolised predominantly by hepatic metabolism via cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.

In humans the one major circulating metabolite (M1) results from desethylation of vardenafil and is subject to further metabolism with a plasma elimination half-life of approximately 4 hours. Parts of M1 are in the form of the glucuronide in systemic circulation. Metabolite M1 shows a phosphodiesterase selectivity profile similar to vardenafil and an in vitro potency for phosphodiesterase type 5 of approximately 28% compared to vardenafil, resulting in an efficacy contribution of about 7%.

The mean terminal half-life of vardenafil in patients receiving vardenafil 10 mg orodispersible tablets ranged between 4 – 6 hours. The elimination half-life of the metabolite M1 is between 3 to 5 hours, similar to parent drug.

The total body clearance of vardenafil is 56 l/h with a resultant terminal half-life of approximately 4-5 hours. After oral administration, vardenafil is excreted as metabolites predominantly in the faeces (approximately 91-95% of the administered dose) and to a lesser extent in the urine (approximately 2-6% of the administered dose).

Pharmacokinetics in special patient groups

Hepatic clearance of vardenafil in healthy elderly volunteers (65 years and over) was reduced as compared to healthy younger volunteers (18 – 45 years). On average elderly males taking vardenafil film-coated tablets had a 52% higher AUC, and a 34% higher Cmax than younger males (see section 4.2).

Vardenafil AUC and Cmax in elderly patients (65 years or over) taking vardenafil orodispersible tablets were increased by 31 to 39% and 16 to 21%, respectively, in comparison to patients aged 45 years and below. Vardenafil was not found to accumulate in the plasma in patients aged 45 years and below or 65 years or over following once-daily dosing of vardenafil 10 mg orodispersible tablets over ten days.

In volunteers with mild to moderate renal impairment (creatinine clearance 30 – 80 ml/min), the pharmacokinetics of vardenafil were similar to that of a normal renal function control group. In volunteers with severe renal impairment (creatinine clearance < 30 ml/min) the mean AUC was increased by 21% and the mean Cmax decreased by 23%, compared to volunteers with no renal impairment. No statistically significant correlation was observed between creatinine clearance and vardenafil exposure (AUC and Cmax ) (see section 4.2). Vardenafil pharmacokinetics has not been studied in patients requiring dialysis (see section 4.3).

In patients with mild to moderate hepatic impairment (Child-Pugh A and B), the clearance of vardenafil was reduced in proportion to the degree of hepatic impairment. In patients with mild hepatic impairment (Child-Pugh A), the mean AUC and Cmax increased 17% and 22% respectively, compared to healthy control subjects. In patients with moderate impairment (Child-Pugh B), the mean AUC and Cmax increased by 160% and 133% respectively, compared to healthy control subjects (see section 4.2). The pharmacokinetics of vardenafil in patients with severely impaired hepatic function (Child-Pugh C) has not been studied (see section 4.3).

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

6. Pharmaceutical particulars

8. Marketing authorisation number(s)

EU/1/03/248/001 Levitra 5 mg film-coated tablet, pack size 2 tablets

EU/1/03/248/002 Levitra 5 mg film-coated tablet, pack size 4 tablets

EU/1/03/248/003 Levitra 5 mg film-coated tablet, pack size 8 tablets

EU/1/03/248/004 Levitra 5 mg film-coated tablet, pack size 12 tablets

EU/1/03/248/005 Levitra 10 mg film-coated tablet, pack size 2 tablets

EU/1/03/248/006 Levitra 10 mg film-coated tablet, pack size 4 tablets

EU/1/03/248/007 Levitra 10 mg film-coated tablet, pack size 8 tablets

EU/1/03/248/008 Levitra 10 mg film-coated tablet, pack size 12 tablets

EU/1/03/248/009 Levitra 20 mg film-coated tablet, pack size 2 tablets

EU/1/03/248/010 Levitra 20 mg film-coated tablet, pack size 4 tablets

EU/1/03/248/011 Levitra 20 mg film-coated tablet, pack size 8 tablets

EU/1/03/248/012 Levitra 20 mg film-coated tablet, pack size 12 tablets

EU/1/03/248/021 Levitra 5 mg film-coated tablet, pack size 20 tablets

EU/1/03/248/022 Levitra 10 mg film-coated tablet, pack size 20 tablets

EU/1/03/248/023 Levitra 20 mg film-coated tablet, pack size 20 tablets

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 6 March 2003

Date of latest renewal: 6 March 2008

10. Date of revision of the text

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu .

Distributed in the United Kingdom by:

What is this medicine?

VARDENAFIL is used to treat erection problems in men. Vardenafil works faster than Sildenafil (Viagra®) and it is less likely to have visual disturbance side effect.

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:
anatomical deformity of the penis, Peyronie’s disease, or ever had an erection that lasted more than 4 hours
bleeding disorder
cancer
diabetes
frequent heartburn or gastroesophageal reflux disease (GERD)
heart disease, angina, high or low blood pressure, a history of heart attack, or other heart problems
high cholesterol
HIV infection
kidney disease
liver disease
sickle cell disease
stroke
stomach or intestinal ulcers
eye or vision problems
an unusual reaction to vardenafil, medicines, foods, dyes, or preservatives

How should this medicine be used?

Take vardenafil tablets by mouth with or without food. The dose is usually taken about 1 hour before sexual activity. Swallow the tablets with a drink of water. Do not take double or extra doses.

Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.

NOTE: This medicine is only for you. Do not share this medicine with others.

What if I miss a dose?

This does not apply. However, do not take double or extra doses.

What may interact with this medicine?

Do not take vardenafil if you are taking the following medications:
nitroglycerin-type drugs for the heart or chest pain such as amyl nitrite, isosorbide dinitrate, isosorbide mononitrate, nitroglycerin, even if these are only taken occasionally. This includes some recreational drugs called ‘poppers’ which also contain amyl nitrate and butyl nitrate.

Vardenafil may also interact with the following medications:
alpha blockers such as alfuzosin (UroXatral®), doxazosin (Cardura®), prazosin (Minipress®), tamsulosin (Flomax®), or terazosin (Hytrin®), used to treat high blood pressure or an enlarged prostate.
arsenic trioxide
bosentan
certain antibiotics such as clarithromycin, erythromycin, sparfloxacin, troleandomycin
certain medicines used for seizures such as carbamazepine, phenytoin, and phenobarbital
certain medicines for the treatment of HIV infection or AIDS
certain medicines to control the heart rhythm (e.g. amiodarone, disopyramide, dofetilide, flecainide, ibutilide, quinidine, procainamide, propafenone, sotalol)
chloroquine
cisapride
diltiazem
grapefruit juice
medicines for fungal infections (fluconazole, itraconazole, ketoconazole, voriconazole)
methadone
nicardipine
pentamidine
pimozide
rifabutin, rifampin, or rifapentine
some medicines for treating depression or mood problems (amoxapine, maprotiline, fluoxetine, fluvoxamine, nefazodone, pimozide, phenothiazines, tricyclic antidepressants)
verapamil

Tell your prescriber or health care professional about all other medicines you are taking, including non-prescription medicines, nutritional supplements, or herbal products. Also tell your prescriber or health care professional if you are a frequent user of drinks with caffeine or alcohol, if you smoke, or if you use illegal drugs. These may affect the way your medicine works. Check with your health care professional before stopping or starting any of your medicines.

What should I watch for while taking this medicine?

If you notice any changes in your vision while taking this drug, notify your prescriber or health care professional as soon as possible. Stop using vardenafil right away if you have a loss of sight in one or both eyes. Contact your healthcare provider immediately.

Contact your physician immediately if the erection lasts longer than 4 hours or if it becomes painful. This may be a sign of priapism and must be treated immediately to prevent permanent damage.

If you experience symptoms of nausea, dizziness, chest pain or arm pain upon initiation of sexual activity after vardenafil use, you should refrain from further activity and should discuss the episode with your prescriber or health care professional as soon as possible.

Do not change the dose of your medication. Please call your prescriber or health care professional to determine if your dose needs to be reevaluated.

Using vardenafil does not protect you or your partner against HIV infection (the virus that causes AIDS) or other sexually transmitted diseases.

What side effects may I notice from this medicine?

Side effects that you should report to your prescriber or health care professional as soon as possible.
back pain
changes in hearing such as loss of hearing or ringing in ears
changes in vision such as loss of vision, blurred vision, eyes being more sensitive to light, or trouble telling the difference between blue and green objects or objects having a blue color tinge to them
chest pain or palpitations
difficulty breathing, shortness of breath
dizziness
eyelid swelling
muscle aches
prolonged erection (lasting longer than 4 hours)
skin rash, itching
seizures

Side effects that usually do not require medical attention (report to your prescriber or health care professional if they continue or are bothersome):
flushing
headache
indigestion
nausea
stuffy nose

This list may not describe all possible side effects.

Where can I keep my medicine?

Keep out of the reach of children.

Store at room temperature between 15 and 30 degrees C (59 and 86 degrees F). Throw away any unused medicine after the expiration date.

Related Posts:

levitra spanien kaufen
buy cheap levitra uk
levitra generic buy
levitra precio peru
levitra generico miglior prezzo
levitra kaufen in spanien
levitra at costco
where to buy levitra in london
levitra 20mg günstig kaufen
viagra levitra cialis costi

  • Facebook
  • Hatena
  • twitter
  • Google+
  • LINE

最強!最高!のビジネスを貴方に

PAGETOP